March 07, 2026 07:37 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Iranian drone strike near Dubai Intl. Airport's terminal forces emergency flight suspensions | 26-year-old Hindu man killed after Holi altercation with Muslim neighbour in Delhi’s Uttam Nagar; four arrested | Zohran Mamdani defends wife amid scrutiny over her 'support' for Palestinian cause | Explosions rock club in Kolkata’s Paikpara, locals claim bombs were stored inside | Iran conflict: White House says US could achieve ‘Operation Epic Fury’ objectives in 4–6 weeks | Sensex, Nifty tumble as global tensions and Dow selloff rattle Indian markets | Two IAF pilots killed as Su-30MKI fighter jet crashes in Assam | 'Who is the US to permit?': Congress slams Modi govt over Trump administration’s waiver on India’s Russian oil purchase | US makes surprise move: India gets 30-day waiver to buy Russian oil amid global supply crisis | India edge England by 7 runs in thriller to reach T20 World Cup 2026 final

Aurobindo Pharma receives USFDA approval for pain reliever tablets

| | May 17, 2016, at 07:19 pm
Hyderabad, May 17 (IBNS) Aurobindo Pharma Limited, manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg, and 8 mg.
Hydromorphone Hydrochloride Tablets is used to relieve moderate to severe pain in patients where the use of an opioid is appropriate, the company release said.
 
The company said that the approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Dilaudid (hydromorphone hydrochloride) Tablets, 2 mg, 4 mg, and 8 mg of Purdue Pharma L.P.
 
Quoting IMS, the company said that the approved product has an estimated market size of US$ 50 million for the twelve months ending March 2016.
 
The company also said this is the 12th ANDA to be approved out of Aurolife formulation facility in New Jersey, US for manufacturing non-antibiotic products and controlled substances, . 
 
Aurobindo now has a total of 263 ANDA approvals (225 Final approvals, including 12 from Aurolife Pharma LLC and 38 tentative approvals) from USFDA.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm